Evidence map›Paper›PMID 34250035›Full record

ArticleFrontiers in cardiovascular medicine2021

Cardiomyocyte Proliferative Capacity Is Restricted in Mice With

Kenji Onoue, Hiroko Wakimoto, Jiangming Jiang, Michael Parfenov, Steven DePalma, David Conner, Joshua Gorham, David McKean, Jonathan G Seidman, Christine E Seidman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cells · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Kenji OnoueDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.
Hiroko WakimotoDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Jiangming JiangDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Michael ParfenovDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Steven DePalmaDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
David ConnerDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Joshua GorhamDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
David McKeanDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Christine E SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Yoshihiko SaitoDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.
Harvard University · USNara Medical University · JP

Funding

Defining Pathways from Gene Mutation to Heart FailureR01HL080494 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI CHEN, CHRISTOPHER S, SEIDMAN, CHRISTINE E · 2005 to 2024
$9.4M
Molecular Signaling in Hypertrophic CardiomyopathyR01HL084553 · NHLBI · HARVARD MEDICAL SCHOOL · PI SEIDMAN, JONATHAN G · 2007 to 2022
$5.9M
NHLBI NIH HHS R01 HL080494NHLBI NIH HHS R01 HL084553
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cell cycledilated cardiomyopathylamin A/Cp21repressed proliferating capacity

Identifiers

PMID34250035
PMCPMC8260675
OpenAlexW3175320176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.